Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Alnylam is making another round of job cuts as it sharpens its focus on the clinical development of its RNAi-based drug candidates. The Cambridge, Mass.-based company, which had 171 employees at the end of September 2011, will trim 33% of its workforce to save roughly $20 million this year. Alnylam will take a $4 million charge in the first quarter related to the restructuring. The move marks the second round of major layoffs at Alnylam, which in September 2010 shed a quarter of its staff after ending a five-year research collaboration with Novartis.
This article has been sent to the following recipient: